Renal and cardiovascular effects of SGLT2 inhibitors among hypertensive patients with chronic kidney disease: A systematic review and meta-analysis
Among hypertensive patients with CKD, SGLT2 inhibitors significantly reduce renal disease progression and cardiovascular events while maintaining favorable safety. These findings support their integration into standard therapy for this high-risk population.
Authors
- Yusra Pintaningrum (ORCID: https://orcid.org/0000-0002-8843-4684)
- Dian Samudra
- Kristian Kurniawan
- Ahmad Surya Dharma
- Renny Anggraeni Puspitasari
- Siska Suridanda Danny (ORCID: https://orcid.org/0000-0002-4518-1410)
- Fauqi Amalia
- Muhammad Almy Firasghani
- Yosua Darmadi Kosen
- Puput Fiohana
- Brianka Yudha Nurpradika
- Andiani
- R.Mohamad Javier
- Iqbal Faizin
- BRM Ario Suryo Kuncoro
Institutions
- Maranatha Christian University (ID)
- Atma Jaya Catholic University of Indonesia (ID)
- University of Mataram (ID)
- UIN Sunan Ampel Surabaya (ID)
- Universitas Muhammadiyah Sidoarjo (ID)
- Pembuluh Darah Harapan Kita (ID)
Publication Details
- Journal
- International Journal of Cardiology Cardiovascular Risk and Prevention
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.ijcrp.2026.200585
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73